Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of MK-7252 in Healthy Adults
NCT03326986Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2017
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of mk-7252 in cancer (3 arms), sponsored by Merck & Co. Primary endpoints: Number of Participants Who Experienced at Least One Adverse Event up to 21 weeks and Number of Participants Who Discontinued Study Treatment Due to an AE up to 19 weeks. Started Nov 2017; status: completed.
02
Drugs
mk-7252
03
Conditions
cancer
Beyond the preview
Go deeper on NCT03326986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03326986.